Application of splicing-associated protein 130 in diagnosis of idiopathic pulmonary interstitial fibrosis and assessment of disease severity

Abstract

The invention relates to application of spliceosome-associated protein 130 (SAP130) in diagnosis of idiopathic pulmonary interstitial fibrosis and assessment of disease severity. Clinical case research finds that the spliceosome-associated protein 130 can be used for diagnosing idiopathic pulmonary interstitial fibrosis and can be used for evaluating the severity of diseases. According to the method, peripheral blood of a patient is directly extracted for SAP130 detection, and the ELISA method is adopted, so that the detection is simple and convenient, and the detection time is short. The diagnosis efficiency and the diagnosis sensitivity are high. The invention provides a new means for diagnosis and disease assessment of idiopathic pulmonary fibrosis.

Description

technical field

[0001] The present invention relates to the field of biomedicine, in particular to the application of splice body-associated protein 130 in the diagnosis of idiopathic pulmonary interstitial fibrosis and the assessment of disease severity. Background technique

[0002] Idiopathic pulmonary fibrosis (IPF) is a common pulmonary interstitial disease, characterized by pulmonary fibrosis, with a prevalence of about (2-29) / 100,000 and a median survival time of only about 3 years. IPF is more common in men, and the prevalence increases significantly with age. The mortality rate of IPF patients worldwide is on the rise. The main symptoms of IPF are progressive dyspnea, eventually leading to respiratory failure or death, and the pathological features are mainly abnormal extracellular matrix deposition and abnormal structural remodeling of lung tissue. At present, more and more studies believe that pulmonary fibrosis is the result of persistent lung injury and abnorm...

Images